

DAFTAR PUSTAKA

- Abbasi, A., Bhutto, A. R., Butt, N., & Munir, S. M. (2012). Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. *Journal of the Pakistan Medical Association*, 62(1), 33–36.
- Alqahtani, A., Khan, Z., Alloghbi, A., Ahmed, T. S. S., Ashraf, M., & Hammouda, D. M. (2019). Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. *Medicina (Lithuania)*, 55(9), 1–22. <https://doi.org/10.3390/medicina55090526>
- Bai, D. S., Zhang, C., Chen, P., Jin, S. J., & Jiang, G. Q. (2017). The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. *Scientific Reports*, 7(1), 1–9. <https://doi.org/10.1038/s41598-017-12834-1>
- Barghini, Valerio; Donnini, Debora; Uzzao, Alessandro; Soardo, G. (2013). Sign and Symptoms of Hepatocellular Carcinoma. *Hepatocellular Carcinoma : Future Outlook*, (table 1), 197–202.
- Bhutiani, N., O'Brien, S. J., Priddy, E. E., Egger, M. E., Hong, Y. K., Mercer, M. K., ... Scoggins, C. R. (2020). Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). *Hpb*, 22(9), 1330–1338. <https://doi.org/10.1016/j.hpb.2019.12.007>
- Bialecki, E. S., & Di Bisceglie, A. M. (2005). Diagnosis of hepatocellular carcinoma. *Hpb*, 7(1), 26–34. <https://doi.org/10.1080/13651820410024049>
- Budihusoso, U. (2014). Karsinoma Hati. In S. Setiati, I. Alwi, A. W. Sudoyo, & B. Setiyohadi (Eds.), *Buku Ajar Ilmu Penyakit Dalam* (6th ed., p. 3040). Jakarta Pusat: InternaPublishing.

- Caviglia, G. P., Ciruolo, M., Abate, M. L., Carucci, P., Rolle, E., Rosso, C., ... Gaia, S. (2020). Alpha-fetoprotein, protein induced by vitamin K absence or antagonist II and glypican-3 for the detection and prediction of hepatocellular carcinoma in patients with cirrhosis of viral etiology. *Cancers*, 12(11), 1–14. <https://doi.org/10.3390/cancers12113218>
- Chan, S. L., Mo, F., Johnson, P. J., Siu, D. Y. W., Chan, M. H. M., Lau, W. Y., ... Yu, S. C. H. (2014). Performance of serum α -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. *Hpb*, 16(4), 366–372. <https://doi.org/10.1111/hpb.12146>
- Chu, Y.-J., Yang, H.-I., & Wu, H.-C. (2017). Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. *Int J Cancer*, 141(4), 711–720. <https://doi.org/10.1002/ijc.30782>.Aflatoxin
- Di Bisceglie, A. M. (2002). Epidemiology and clinical presentation of hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology*, 13(9 II), 169–171. [https://doi.org/10.1016/s1051-0443\(07\)61783-7](https://doi.org/10.1016/s1051-0443(07)61783-7)
- Din, R. U., Qadir, A., Ali, R. S., & Salama, A. (2020). *Hepatocellular Carcinoma: Correlation of Alpha-Fetoprotein with Tumour Characteristics*. 70(2), 420–424.
- Falkson, G., Falkson, C. I., & Garbers, L. M. (1998). Hepatocellular carcinoma. *Cancer Treatment and Research*, 98, 83–109. https://doi.org/10.1007/978-1-4615-4977-2_4
- Feng, H., Li, B., Li, Z., Wei, Q., & Ren, L. (2021). PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. *BMC Cancer*, 21(1), 1–10. <https://doi.org/10.1186/s12885-021->

08138-3

- Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. *Lancet*, 391(10127), 1301–1314. [https://doi.org/10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)
- Friedman, S. L. (2008). Mechanisms of Hepatic Fibrogenesis. *Gastroenterology*, 134(6), 1655–1669. <https://doi.org/10.1053/j.gastro.2008.03.003>
- Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J. L., ... Vilgrain, V. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, 69(1), 182–236. <https://doi.org/10.1016/j.jhep.2018.03.019>
- Garcia-Tsao, G. (2016). The Child–Turcotte Classification: From Gestalt to Sophisticated Statistics and Back. *Digestive Diseases and Sciences*, 61(11), 3102–3104. <https://doi.org/10.1007/s10620-016-4319-7>
- Ho, D. W. H., Lo, R. C. L., Chan, L. K., & Ng, I. O. L. (2016). Molecular pathogenesis of hepatocellular carcinoma. *Liver Cancer*, 5(4), 290–302. <https://doi.org/10.1159/000449340>
- Hulley, S. B., Cummings, S. R., & Browner, W. S. (2013). *Designing Clinical Research* (4th ed.). Philadelphia: Lippincott Williams & Wilkins.
- Jasirwan, C. O. M., Fahira, A., Siregar, L., & Loho, I. (2020). The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. *BMC Gastroenterology*, 20(1), 1–8. <https://doi.org/10.1186/s12876-020-01365-1>
- Kamarajah, S. K., Frankel, T. L., Sonnenday, C., Cho, C. S., & Nathan, H. (2018). Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A

Surveillance, Epidemiology, End Results (SEER) analysis. *Journal of Surgical Oncology*, 117(4), 644–650. <https://doi.org/10.1002/jso.24908>

Kumar, V., Abbas, A. K., & Aster, J. C. (2018). *Robbins Basic Pathology* (10th ed.). Philadelphia: Elsevier.

Lim, T. S., Kim, D. Y., Han, K. H., Kim, H. S., Shin, S. H., Jung, K. S., ... Ahn, S. H. (2016). Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. *Scandinavian Journal of Gastroenterology*, 51(3), 344–353. <https://doi.org/10.3109/00365521.2015.1082190>

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., ... Finn, R. S. (2021). Hepatocellular carcinoma. *Nature Reviews Disease Primers*, 7(1). <https://doi.org/10.1038/s41572-020-00240-3>

Muscari, F., & Maulat, C. (2020). Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): Is this 50-year biomarker still up-to-date? *Translational Gastroenterology and Hepatology*, 5, 2019–2021. <https://doi.org/10.21037/tgh.2019.12.09>

Napitupulu, E. N. (2018). *KORELASI SERUM ALFA FETOPROTEIN DENGAN KURAN DAN JUMLAH TUMOR PADA KARSINOMA HEPATOSELULER* Eristan N Napitupulu, Dr. dr. Bagaswoto P, Sp.Rad(K), Sp.KN, M.Kes, FICA. 6.

Nault, J. C. (2017). Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator. *Gastroenterology*, 152(5), 941–943. <https://doi.org/10.1053/j.gastro.2017.02.031>

Nault, J. C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E. S., Bioulac-Sage, P., ... Zucman-Rossi, J. (2014). Telomerase reverse transcriptase

promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. *Hepatology*, 60(6), 1983–1992. <https://doi.org/10.1002/hep.27372>

Ng, J., & Wu, J. (2012). Hepatitis B-and hepatitis C-related hepatocellular carcinomas in the united states: Similarities and differences. *Hepatitis Monthly*, 12(10 HCC), 83–92. <https://doi.org/10.5812/hepatmon.7635>

Nurdjanah, S. (2014). Sirosis Hati. In S. Setiati, I. Alwi, A. W. Sudoyo, & B. Setiyohadi (Eds.), *Buku Ajar Ilmu Penyakit Dalam* (6th ed., p. 1978). Jakarta Pusat: InternaPublishing.

Okuda, K., Kondo, Y., & Nakano, M. (1991). Leukocytosis : Report of Five Cases. *Hepatology*, 13(4), 695–700. <https://doi.org/10.1002/hep.1840130414>

Omata, M., Cheng, A. L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., ... Sarin, S. K. (2017). Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatology International*, 11(4), 317–370. <https://doi.org/10.1007/s12072-017-9799-9>

Park, S. J., Jang, J. Y., Jeong, S. W., Cho, Y. K., Lee, S. H., Kim, S. G., ... Bang, H. I. (2017). Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. *Medicine (United States)*, 96(11). <https://doi.org/10.1097/MD.00000000000005811>

Rebouissou, S., & Nault, J. C. (2020). Advances in molecular classification and precision oncology in hepatocellular carcinoma. *Journal of Hepatology*, 72(2), 215–229. <https://doi.org/10.1016/j.jhep.2019.08.017>

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., ... Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *Journal of Hepatology*, 76(3), 681–693.

<https://doi.org/10.1016/j.jhep.2021.11.018>

Rodríguez, R. G., Gutiérrez, M. R., Varasa, T. A., Frutos, C. G., Dopazo, J. J. C., Pérez, G. de la C., & Ruano, J. J. S. (2012). Prognostic staging system "Barcelona Clinic Liver Cancer "and alpha-fetoprotein in hepatocellular carcinoma. *Revista Espanola de Enfermedades Digestivas*, 104(6), 298–304.

<https://doi.org/10.4321/s1130-01082012000600003>

Selvanathan, M., & Jayabalan, N. (2020). *EMPLOYEE PRODUCTIVITY IN MALAYSIAN PRIVATE HIGHER*. (November), 1948–1949.

<https://doi.org/10.48080/jae.v17i3.50>

Senturk, E., & Manfredi, J. J. (2013). P53 and cell cycle effects after DNA damage. *Methods in Molecular Biology*, 962(1), 49–61. https://doi.org/10.1007/978-1-62703-236-0_4

Septianti, R., Ratnasari, N., & Nurdjanah, S. (2018). *Perbedaan rasio alpha fetoprotein-l3 / alpha fetoprotein (afp- l3%) pada karsinoma hepatoseluler berdasarkan sistim staging barcelona clinic liver cancer (bclc) 1*. Universitas Gadjah Mada.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

Tellapuri, S., Sutphin, P. D., Beg, M. S., Singal, A. G., & Kalva, S. P. (2018). Staging systems of hepatocellular carcinoma: A review. *Indian Journal of Gastroenterology*, 37(6), 481–491. <https://doi.org/10.1007/s12664-018-0915-0>

- The Global Cancer Observatory. (2020). Cancer Incident in Indonesia. *International Agency for Research on Cancer*, 858, 1–2. Retrieved from <https://gco.iarc.fr/>
- Yang, Y., Li, G., Lu, Z., Liu, Y., Kong, J., & Liu, J. (2021). Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. *Frontiers in Oncology*, 11(November), 1–10. <https://doi.org/10.3389/fonc.2021.726213>
- Zhang, J., Chen, G., Zhang, P., Zhang, J., Li, X., Gan, D., ... Ye, Y. (2020). The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *PLoS ONE*, 15(2), 1–21. <https://doi.org/10.1371/journal.pone.0228857>
- Zhou, J. M., Wang, T., & Zhang, K. H. (2021). AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. *Medicine*, 100(43), e27673. <https://doi.org/10.1097/MD.00000000000027673>
- Zhu, R. X., Seto, W. K., Lai, C. L., & Yuen, M. F. (2016). Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. *Gut and Liver*, 10(3), 332–339. <https://doi.org/10.5009/gnl15257>